about
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to addr...
Read More
26.03
-0.28
(-1.06%)
1.6M
XNAS Volume
XNAS 09 Jan, 2026 4:30 PM (EST)
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Immunovant Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..